Abstract: The management of advanced lung cancer has been transformed with the identification of targetable oncogenic driver alterations. This includes anaplastic lymphoma kinase (ALK) gene rearrangements. ALK tyrosine kinase inhibitors (TKI) are established first-line treatment options in advanced ALK rearranged non-small cell lung cancer (NSCLC), with several next-generation ALK TKIs (alectinib, brigatinib, ensartinib and lorlatinib) demonstrating survival benefit compared with the first-generation ALK TKI crizotinib. Still, despite high objective response rates and durable progression-free survival, drug resistance inevitably ensues, and treatment options beyond ALK TKI are predominantly limited to cytotoxic chemotherapy. Anti-angiogenic therapy targeting the vascular endothelial growth factor (VEGF) signaling pathway has shown efficacy in combination with platinum-doublet chemotherapy in advanced NSCLC without a driver alteration, and with EGFR TKI in advanced EGFR mutated NSCLC. The role for anti-angiogenic therapy in ALK rearranged NSCLC, however, remains to be elucidated. This review will discuss the pre-clinical rationale, clinical trial evidence to date, and future directions to evaluate anti-angiogenic therapy in ALK rearranged NSCLC.

Keywords: anaplastic lymphoma kinase; ALK rearrangement; anti-angiogenesis; non-small cell lung cancer; vascular endothelial growth factor

1. Introduction

The management of advanced lung cancer has been transformed with the identification of targetable oncogenic driver alterations [1]. Notably, this includes anaplastic lymphoma kinase (ALK) gene rearrangements, which are detected in approximately 3–7% of patients with advanced non-small cell lung cancer (NSCLC) [2]. The most common gene fusion partner is echinoderm microtubule-associated protein-like 4 (EML4), which accounts for approximately 95% of ALK fusion variants, although a large range of other gene fusion partners have been reported [3]. ALK gene fusions lead to the aberrant oncogenic activation of the ALK tyrosine kinase [4]. Most ALK fusion variants in NSCLC have demonstrated sensitivity to ALK tyrosine kinase inhibitors (TKI) [3]. ALK TKI are established first-line treatment options in advanced ALK rearranged NSCLC, with several next-generation ALK TKIs (alectinib [5,6], brigatinib [7], ensartinib [8] and lorlatinib [9]) demonstrating survival benefit compared with the first-generation ALK TKI crizotinib in phase III randomized controlled trials. Consequently, there are an expanding number of oral targeted therapy options in the first-line treatment-naïve setting. Still, despite high objective response rates and durable progression-free survival, drug resistance inevitably ensues. Lorlatinib, a third-generation ALK TKI, has shown efficacy in the setting of resistance to prior first- and/or second-generation ALK TKI [10]. Beyond ALK TKI, however, treatment options remain predominantly limited to cytotoxic chemotherapy. Anti-angiogenic therapy, targeting the vascular endothelial growth factor (VEGF) signaling pathway, has shown efficacy in combination with platinum-doublet chemotherapy in advanced NSCLC without a driver...
alteration, and with EGFR TKI in advanced EGFR mutated NSCLC [11]. The role for anti-angiogenic therapy in ALK rearranged NSCLC, however, remains to be elucidated. This review will discuss the pre-clinical rationale, clinical trial evidence to date, and future directions to evaluate anti-angiogenic therapy in ALK rearranged NSCLC.

2. VEGF and Angiogenesis

The VEGF family consists of polypeptide growth factors including VEGF-A, -B, -C, -D, and -E [12]. VEGF-A is a key regulator of blood vessel development in adult tissues. VEGFs bind to receptors, consisting of three variants, VEGFR-1, -2 and -3 (Figure 1). This results in the formation of receptor homo- or heterodimers, activating downstream signaling pathways. VEGF expression is mediated by numerous growth factors, cytokines and hypoxia. In tumors, VEGF expressed by cancer cells can sustain tumor growth, commonly via the hypoxia-response pathway [13]. This pathway may be driven by hypoxia-inducible factors (HIFs) such as HIF-1, a heterodimer that binds to hypoxia-response elements and activates VEGF transcription. Given its key role in promoting angiogenesis and tumor proliferation, targeting VEGF with anti-angiogenic therapies has become a key strategy for cancer treatment [14].

Figure 1. VEGF activation and signaling pathway. The VEGF protein family includes VEGF-A, -B, -C, -D, and -E. VEGF-A binds to VEGFR1 homo-, VEGFR2 homo- and VEGFR1/R2 hetero-dimers, VEGF-B binds to VEGFR1 homodimers, VEGF-C and -D bind to VEGFR3 homodimers and VEGF-E binds to VEGFR2 homodimers.

3. Pre-Clinical Evidence for Anti-Angiogenic Therapy in NSCLC

3.1. Targeting the VEGF Axis in NSCLC

Targeting of the VEGF axis has a long history in advanced NSCLC. Bevacizumab, an anti-VEGF monoclonal antibody, was one of the first approved targeted therapies for non-squamous NSCLC nearly two decades ago, in combination with carboplatin plus paclitaxel chemotherapy [15]. Widespread adoption into the treatment paradigm for NSCLC was however limited by the modest survival benefits in conjunction with cost and drug toxicity considerations [16]. As the therapeutic landscape has evolved, with a growing number of targeted and immunotherapies leading to improved survival for patients with advanced NSCLC [17], the role for anti-angiogenic therapy is being revisited. This is further supported
by a building body of pre-clinical evidence, suggesting that targeting of the VEGF axis may not only inhibit angiogenesis, but may also trigger anti-tumor immunity [18].

VEGF targeting therapies may exert broad anti-tumor and anti-angiogenic effects through direct inhibition of vessel growth inducing regional cancer cell death, induction of endothelial cell apoptosis through activation of BCL2 or Akt signaling, and stopping the recruitment of hematopoietic or endothelial progenitor cells for new vessel formation [19–22]. With an increased understanding of the importance of the tumor immune microenvironment, more recent studies have shown that VEGF inhibition may also have an immunomodulatory effect. A more immune permissive rather than immunosuppressive microenvironment may result from increased T-cell tumor infiltration and enhanced promotion of dendritic cell maturation [23,24]. Tumor endothelial cells (EC) may play a key role in this process. Anti-angiogenic therapy may restore proinflammatory surface proteins on tumor ECs through a process termed ‘vessel normalization’ [25]. This may not only improve immune cell activation and infiltration but may also enhance drug delivery into tumors with the formation of high endothelial venules (HEVs) [26,27]. Taken together, this has led to the evaluation of combinatorial approaches, particularly with immunotherapy (such as anti-PD-1/L1 inhibitors), and targeted therapies.

3.2. Pre-Clinical Evidence for ALK Rearranged NSCLC

For ALK rearranged NSCLC, there is a small body of pre-clinical evidence which supports the role for anti-angiogenic therapy. In a study by Watanabe et al. [28], combination ALK TKI (alectinib and crizotinib) with anti-VEGF2 therapy was evaluated in mouse xenograft models. Key findings included enhanced anti-tumor proliferative effects from the combination therapies compared with ALK TKI alone, induction of VEGFR2 expression after exposure to ALK TKI, implicating the role of VEGFR2 signaling with ALK TKI treatment, and lower numbers of CD31-positive blood vessels in mice treated with the combination treatment, suggesting anti-angiogenic efficacy. Importantly, VEGFR2 RNA expression was elevated in ALK-driven NSCLC cells, further increased after ALK TKI treatment, and decreased transiently after treatment. This implicates an important role for the VEGFR2 signaling pathway in ALK rearranged NSCLC. Further studies have demonstrated RAS-MAPK dependence as a hallmark of EML4-ALK rearranged NSCLC, with reactivation of the MAPK pathway associated with resistance to ALK inhibition [29]. Similarly, VEGF signaling may activate the MAPK pathway, as well as the PI3K/Akt pathway [30,31]. Another potential mechanism by which ALK and VEGF signaling may interact is through hypoxia pathways. Martinengo et al. [32] previously demonstrated that hypoxia pathways were significantly enriched in ALK rearranged NSCLC, compared with EGFR and KRAS-mutated NSCLC. ALK regulated VEGFA production and tumor angiogenesis in NSCLC, dependent on both HIF1α and HIF2α. Koh et al. [33] also demonstrated that ALK-translocated tumor cells may upregulate PD-L1 expression via enhanced HIF1α expression. Taken together, this suggests that dual blockade of ALK and VEGF may represent a rational combination approach. The potential cross-talk between the VEGF and ALK signaling pathways is shown in Figure 2. Combination approaches, however, should be cognizant of bioavailability and potential pharmacokinetic interactions. In particular, the drug eflux functions of P-glycoprotein and ATP-binding cassette super-family G member 2 (ABCG2) may be important for the bioavailability and distribution of ALK and VEGF TKIs [34–37].
which have demonstrated important roles in tumor angiogenesis [51–53]. Conversely, ways include fibroblast growth factors (FGFs), which may induce angiogenesis through immunotherapy or targeted therapy.

VEGF resistant tumors [46,47]. Platelet-derived growth factor (PDGF) signaling leads to pro-angiogenic factor secretion, with subsequent increase in EC proliferation, migration, sprouting and tube formation [48]. Tumor revascularization due to PDGF signaling has been demonstrated in various tumors [49,50]. Hepatocyte growth factor (HGF)/c-MET, placental growth factor (PIGF) and angiopoietins are other pro-angiogenic factors or activation of alternative VEGF-independent angiogenic pathways [44]. Therefore, other targets or targeted therapies may also be considered in targeting angiogenesis pathways in NSCLC. To this end, multi-kinase TKIs may also act through complementary mechanisms, although the sensitivity for each target may differ, and similarly across different compounds. Therefore, it may be important to consider each multi-kinase TKI individually, in regard to kinase inhibition. Examples of other factors or alternative pathways include fibroblast growth factors (FGFs), which may induce angiogenesis through the enhanced proliferation and migration of endothelial cells [45]. Pre-clinical studies have demonstrated the increased expression of FGF and/or FGFR upon hypoxia in anti-VEGF resistant tumors [46,47]. Platelet-derived growth factor (PDGF) signaling leads to pro-angiogenic factor secretion, with subsequent increase in EC proliferation, migration, sprouting and tube formation [48]. Tumor revascularization due to PDGF signaling has been demonstrated in various tumors [49,50]. Hepatocyte growth factor (HGF)/c-MET, placental growth factor (PIGF) and angiopoietins are other pro-angiogenic factors which have demonstrated important roles in tumor angiogenesis [51–53]. Conversely, natural anti-angiogenic factors also represent potential therapeutic agents. These include thrombospondin, pigment epithelium-derived factor (PEDF) and endostatin, a C-terminal fragment of type XVIII collagen [54]. In particular, a human recombinant endostatin,
Endostar, has been evaluated in numerous clinical trials for NSCLC, demonstrating efficacy in combination with chemotherapy [55,56].

4. Clinical Evidence for Anti-Angiogenic Therapy in ALK Rearranged NSCLC

4.1. Anti-Angiogenic Therapy in Unselected NSCLC Populations

Several anti-angiogenic therapies have been evaluated in NSCLC. Most prominently, this includes monoclonal antibodies targeting VEGF such as bevacizumab and ramucirumab. Bevacizumab is a humanized monoclonal antibody which targets VEGF-A, whilst ramucirumab is a humanized monoclonal antibody which selectively targets VEGFR2 [57]. In addition, multi-kinase TKIs have been tested in NSCLC, such as nintedanib. Nintedanib targets several major angiogenic pathways, with activity against the PDGF, FGF and VEGF receptor families [58]. Previous trials and meta-analyses have demonstrated the efficacy for combination anti-VEGF therapy with chemotherapy in both the first- and second-line treatment settings with improved progression-free survival (PFS) and objective response rates (ORR) compared with chemotherapy alone [16,59–63]. This includes first-line carboplatin and paclitaxel with bevacizumab [64] and second-line docetaxel with ramucirumab [65] and docetaxel with nintedanib [66]. This led to the regulatory approval of these anti-angiogenic therapies with efficacy demonstrated in randomized phase III trials. A wide range of other monoclonal antibodies such as aflibercept [67], and TKIs such as axitinib [68], cediranib [69–71], linifanib [72], motesanib [73], sunitinib [74] and vandetanib [76–79], were also evaluated in randomized trials for NSCLC in both the first- and later-line settings. A human recombinant endostatin, Endostar, has also demonstrated efficacy in numerous randomized trials for advanced NSCLC as mentioned above, and has received regulatory approval in China [80].

Ultimately, however, concerns relating to costs, toxicities and lack of overall survival (OS) benefit limited the reimbursement and utilization of anti-angiogenic therapies in routine clinical practice. For example, a meta-analysis by Raphael et al. [59] of phase III trials demonstrated improvement in ORR and PFS, but no significant effect on OS. In another meta-analysis by Li et al. [81] of 15 randomized controlled phase II and III trials of anti-angiogenic TKIs in combination with chemotherapy versus chemotherapy alone, PFS and ORR were significantly increased. However, there was no difference in OS. Furthermore, grade ≥3 toxicities and treatment-related deaths were significantly higher with the combination of anti-angiogenic therapy with chemotherapy. Many of the trials evaluating anti-angiogenic agents, however, were conducted in unselected NSCLC populations, or where the EGFR/ALK status was unknown or not tested. With the introduction of immunotherapy into the treatment paradigm, more recent trials have further demonstrated the efficacy of anti-angiogenic therapy in combination with chemoimmunotherapy.

4.2. Combination Anti-Angiogenic Therapy with Chemoimmunotherapy

IMpower150 was a three-arm randomized controlled phase III trial for treatment-naïve patients with advanced non-squamous NSCLC [82]. The regimens in the three arms consisted of bevacizumab/carboplatin/paclitaxel (BCP), atezolizumab/carboplatin/paclitaxel (ACP) and atezolizumab/bevacizumab/carboplatin/paclitaxel (ABCP). In EGFR/ALK negative patients, median PFS (HR 0.62, 95%CI 0.52–0.74) and median OS (HR 0.80, 95%CI 0.67–0.95) were both prolonged with ABCP compared with BCP [83]. There was no statistically significant difference in OS comparing the ACP and BCP arms (HR 0.84, 95%CI 0.71–1.00). Importantly, however, this trial allowed patients with EGFR/ALK alterations after prior TKI treatment, reported separately as a subgroup analysis [84]. There were a total of 40 patients with ALK rearrangements treated on the trial, including n = 11 in the ABCP group, n = 9 in the ACP group and n = 20 in the BCP group (Table 1). PFS results for ALK rearranged patients were reported only together with EGFR mutated patients (n = 108 total), with PFS improvement for ABCP compared with BCP (9.7 versus 6.1 months, HR 0.59, 95%CI 0.37–0.94) [82]. OS results for the ALK rearranged subgroup, however, were subsequently reported—although the small numbers in each arm likely contributed to
wide confidence intervals. In 31 patients, ABCP compared with BCP demonstrated median OS of not reached (NR) versus 6.9 months (HR 0.47, 95%CI 0.15–1.48). In 29 patients, ACP compared with BCP demonstrated a median OS of 13.6 versus 6.9 months (HR 0.59, 95%CI 0.20–1.72). Subsequently, there have also been several case reports documenting the potential use of the ABCP regimen in the post ALK TKI setting [85,86]. However, there remains no other prospective evidence to date of combination anti-angiogenic therapy with chemoinmunotherapy [87].

4.3. Combination Anti-Angiogenic Therapy with Targeted Therapy

Anti-angiogenic therapy in combination with targeted therapy has been most comprehensively evaluated in EGFR mutated NSCLC. Combinations of erlotinib with bevacizumab [88] and erlotinib with ramucirumab [89] have both demonstrated superior outcomes compared with erlotinib alone in randomized phase III trials. Consequently, this could be considered a standard treatment option in the first-line setting for advanced EGFR mutated NSCLC. In ALK rearranged NSCLC, the reported evidence to date of combination anti-angiogenic therapy with ALK TKI is more limited. The combination of crizotinib plus bevacizumab has been reported in a small single-arm prospective observational study, which included 12 treatment-naïve patients with ALK rearrangements [90]. The ORR was 58.3% and the disease control rate (DCR) was 100%. After median follow-up of 42.8 months, median PFS was 13.9 months and median duration of response (DOR) was 14.8 months. Fatigue (28.6%) and rash (21.4%) were the most common side effects reported, however three patients discontinued due to liver toxicity or hemoptysis. More recently, alectinib plus bevacizumab has also been evaluated in two single-arm trials. A phase I/II study of alectinib plus bevacizumab utilized a dose de-escalation strategy in the phase I portion of the study [91]. There were no dose-limiting toxicities at the standard doses of both drugs (alectinib 600 mg oral twice daily and bevacizumab 15 mg/kg intravenously every 3 weeks), and this was determined as the recommended phase II dose (RP2D). In total, there were 11 patients treated on the study, of which six (55%) were treatment-naïve, with the remaining patients having received prior ALK TKI but were alectinib-naïve. Median PFS was not reached and was 9.5 months in the treatment-naïve and ALK TKI pre-treated patients, respectively. Grade 3 or higher adverse events included pneumonitis (9%), proteinuria (9%), and hypertension (9%). The study, however, was closed prematurely due to slow accrual. Another single-arm phase II study of alectinib plus bevacizumab was conducted in Japan, using the standard local dose of alectinib (300 mg oral twice daily) with bevacizumab (15 mg/kg every 3 weeks) [92]. Patients in this study (n = 12) had progressed on prior alectinib, with 11 (92%) also having received prior crizotinib. The median PFS was 3.1 months with an ORR of 8% and DCR of 67%. Grade 3 or higher adverse events included anemia (8%), proteinuria (8%), diarrhea (8%) and hypokalemia (8%). A further single-arm phase II trial of alectinib and bevacizumab is currently ongoing (NCT03779191), however results are yet to be reported. Lastly, the combination of lorlatinib plus bevacizumab has been reported in a small case series of two patients resistant to prior ALK TKI, with disease regression and disease control (although with symptomatic improvement) after combination treatment, respectively [93]. The combination treatment was well tolerated, with bevacizumab given at doses of 15 mg/kg and 10 mg/kg every 3 weeks, respectively.
Table 1. Clinical trials evaluating anti-angiogenic therapy in ALK rearranged NSCLC.

| Study                          | Study Type     | Study Population (No. of Patients) | Treatment                                                   | ORR (%) | Median PFS (Months) | Median OS (Months) | Ref.         |
|-------------------------------|----------------|-----------------------------------|-------------------------------------------------------------|---------|--------------------|--------------------|--------------|
| IMpower150                    | Phase III RCT  | ALK TKI pre-treated (n = 40)      | ABCP versus BCP versus ACP                                 | -       | -                  | ABCP versus BCP versus ACP versus BCP—NR versus ACP | [84]         |
| Lin et al., 2021              | Phase I/II     | Treatment-naive (n = 6) and ALK   | Alectinib 600 mg PO BD plus bevacizumab IV q3w              | 82      | -                  | Treatment naïve cohort—NR ALK TKI pre-treated cohort—9.5 | [91]         |
| Watanabe et al., 2019         | Single-arm phase II | Alectinib pre-treated (n = 12)   | Alectinib 300 mg PO BD plus bevacizumab 15 mg/kg IV q3w    | 8       | 3.1                | -                  | [92]         |
| Huang et al., 2021            | Single-arm observational | Treatment-naive (n = 12) | Crizotinib 250 mg PO BD plus bevacizumab 7.5 mg/kg IV q3w | 58.3    | 13.9               | -                  | [90]         |

ABCP—atezolizumab, bevacizumab, carboplatin, paclitaxel; ACP—atezolizumab, carboplatin, paclitaxel; ALK—anaplastic lymphoma kinase; BCP—bevacizumab, carboplatin, paclitaxel; NR—not reached; ORR—objective response rate; OS—overall survival; PFS—progression-free survival; TKI—tyrosine kinase inhibitor.

5. Future Directions to Evaluate Anti-Angiogenic Therapy in ALK Rearranged NSCLC

Despite growing evidence for the efficacy of anti-angiogenic therapy in non-oncogene driven NSCLC and EGFR mutated NSCLC, there remain limited data on the efficacy of anti-angiogenic therapy in ALK rearranged patients. Prospective data are scarce, and difficulties in recruiting patients to trials for a relatively uncommon driver alteration is compounded by the large number of potential combination approaches with targeted therapies and chemoimmunotherapy. Interestingly, the ABCP regimen has received regulatory approval for ALK rearranged (and EGFR mutated) patients in Europe and Japan after prior TKI failure [83]. Although not statistically powered to detect differences between arms in the IMpower150 trial, the reported OS data in ALK rearranged patients suggest the added efficacy with bevacizumab may be limited. This emphasizes the need for larger datasets and greater evidence to evaluate the four-drug regimen, where costs and toxicities remain a prominent consideration. Similarly, the prospective evidence for combination ALK TKI with bevacizumab suggests only modest efficacy, particularly in ALK TKI pre-treated patients. Several ongoing trials will add to the evidence base. This includes the aforementioned single-arm trial of alectinib plus bevacizumab (NCT03779191), as well as a phase I trial of brigatinib plus bevacizumab (NCT04227028). In addition, a phase I trial evaluating the combination of ensartinib with carboplatin, pemetrexed and bevacizumab (NCT04837716) will provide preliminary evidence on the novel combination of ALK TKI with anti-angiogenic therapy and chemotherapy. This trial will use a dose de-escalation strategy, followed by a dose-expansion study. A note of caution, however, may be observed from trials evaluating the combination of ALK TKI with immunotherapy, in which toxicity was significantly increased, without signs of greater efficacy [94,95]. Whilst results from these ongoing trials will provide additional data, sample sizes are likely to be small. This highlights the need for alternative and innovative methods of generating high-quality and robust clinical evidence. Real-world evidence and big data initiatives may play a broader role in complementing clinical trial data in this regard [96].

Nevertheless, despite modest evidence to date, in selected patients anti-angiogenic therapy may still have an important role. Given the propensity for ALK rearranged NSCLC to develop central nervous system (CNS) metastases, and the activity of bevacizumab for radiation necrosis [97], this may be a specific subset of patients that may benefit from
bevacizumab therapy. A small case series has demonstrated the potential efficacy of bevacizumab in combination with continued ALK TKI in managing brain radiation necrosis [98].

A further consideration apart from the optimal combination is the optimal line of therapy and therapeutic sequencing [99]. With several generations of ALK TKI, the treatment landscape is increasingly more complex. After progression on first-line ALK TKI, treatment options may include sequencing with next-generation ALK TKI, chemotherapy or chemoinmunotherapy, or even rechallenge with prior ALK TKI. Potentially, anti-angiogenic therapy could be considered in combination with all of these options, whether as an on- or off-label treatment. Emerging data relating to on-target and off-target mechanisms of resistance further add to the complexity for treatment decision making [100]. Relatedly, a case report suggested bevacizumab may have reversed primary resistance to alectinib in a patient after combined bevacizumab plus chemotherapy treatment [101]. The patient subsequently responded to rechallenge with alectinib. Interestingly, in this case, patient-derived cell lines taken before and after initial alectinib therapy were sensitive to alectinib ex vivo. Consequently, it was hypothesized that bevacizumab may have normalized the tumor vasculature to allow improved delivery of alectinib into the tumor, suggesting that the TME may have been responsible for the initial primary resistance to alectinib. In this context, translational research for predictive biomarkers for anti-angiogenic therapy efficacy becomes of paramount importance. Rigorous pre-clinical and translational studies are needed to better elucidate key patient and tumor characteristics that may predict for response and identify rational combination approaches.

Ultimately, with prospective clinical trial data likely to be limited, greater pre-clinical and translational evidence will be crucial to elucidate the role for anti-angiogenic therapy in ALK rearranged NSCLC. We have increasing understanding of the molecular heterogeneity of lung cancer. In particular, stark underlying biologic differences of oncogenic driven lung cancers with gene rearrangements compared to activating gene mutations [102] point towards a need to consider these subgroups separately. Finally, high-quality real-world studies may also represent the most feasible method to generate clinical evidence in this area of unmet need.

6. Conclusions

There is now a large body of evidence supporting the role of anti-angiogenic therapy in the treatment paradigm for advanced lung cancer. For ALK rearranged NSCLC however, the evidence is limited, and prospective clinical data suggest only modest efficacy. Greater evidence to support the use of anti-angiogenic therapy in ALK rearranged NSCLC is needed, including pre-clinical, translational, and clinical data.

Author Contributions: Writing—original draft preparation, A.C.T.; writing—review and editing, A.C.T. and N.P. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: A.C.T. reports consultant or advisory roles for Amgen and Pfizer outside the submitted work. N.P. reports advisory roles for Boehringer Ingelheim, MSD, Merck, BMS, Astra Zeneca, Takeda, Pfizer, and Roche; reports speaking honoraria from Boehringer Ingelheim, Bayer, Novartis, Pfizer, Roche, Takeda, and Ipsen; research funding to institution from Bayer, Pfizer, and Roche; all outside the submitted work.
References

1. Tan, A.C.; Tan, D.S.W. Targeted Therapies for Lung Cancer Patients with Oncogenic Driver Molecular Alterations. J. Clin. Oncol. 2022, 40, 611–625. [CrossRef] [PubMed]

2. Herbst, R.S.; Morgenstern, D.; Boshoff, C. The Biology and Management of Non-Small Cell Lung Cancer. Nature 2018, 553, 446–454. [CrossRef] [PubMed]

3. Ou, S.-H.I.; Zhu, V.W.; Nagasaka, M. Catalog of 5’ Fusion Partners in ALK-Positive NSCLC Circa 2020. JTO Clin. Res. Rep. 2020, 1, 100015. [CrossRef] [PubMed]

4. Shaw, A.T.; Hsu, P.P.; Awad, M.M.; Engelman, J.A. Tyrosine Kinase Gene Rearrangements in Epithelial Malignancies. Nat. Rev. Cancer 2013, 13, 772–787. [CrossRef] [PubMed]

5. Hida, T.; Nokiha, H.; Kondo, M.; Kim, Y.H.; Azuma, K.; Seto, T.; Takiguchi, Y.; Nishio, M.; Yoshioka, H.; Imamura, F.; et al. Alectinib versus Crizotinib in Patients with ALK-Positive Non-Small-Cell Lung Cancer (J-ALEX): An Open-Label, Randomised Phase 3 Trial. Lancet 2017, 389, 29–39. [CrossRef]

6. Peters, S.; Camidge, D.R.; Shaw, A.T.; Gadgeel, S.; Ahn, J.S.; Kim, D.-W.; Ou, S.-H.I.; Pérol, M.; Dziadziuszko, R.; Rosell, R.; et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2017, 377, 829–838. [CrossRef] [PubMed]

7. Peters, S.; Camidge, D.R.; Shaw, A.T.; Gadgeel, S.; Ahn, J.S.; Kim, D.-W.; Ou, S.-H.I.; Pérol, M.; Dziadziuszko, R.; Rosell, R.; et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2017, 377, 829–838. [CrossRef] [PubMed]

8. Shaw, A.T.; Bauer, T.M.; de Marinis, F.; Felip, E.; Goto, Y.; Liu, G.; Mazieres, J.; Kim, D.-W.; Mok, T.; Polli, A.; et al. First-Line Erlotinib or Crizotinib in Patients with Anaplastic Lymphoma Kinase–Positive Non-Small-Cell Lung Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021, 7, 1617–1625. [CrossRef] [PubMed]

9. Shaw, A.T.; Bauer, T.M.; de Marinis, F.; Felip, E.; Goto, Y.; Liu, G.; Mazieres, J.; Kim, D.-W.; Mok, T.; Polli, A.; et al. First-Line Erlotinib or Crizotinib in Patients with Anaplastic Lymphoma Kinase–Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2020, 383, 2018–2029. [CrossRef]

10. Libshitz, B.; Besse, B.; Bauer, T.M.; Felip, E.; Soo, R.A.; Camidge, D.R.; Chiari, R.; Beazr, A.; Lin, C.-C.; Gadgeel, S.M.; et al. Lorlatinib in Patients with ALK-Positive Non-Small-Cell Lung Cancer: Results from a Global Phase 2 Study. Lancet Oncol. 2018, 19, 1654–1667. [CrossRef]

11. Perdrizet, K.; Leighl, N.B. The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small-Cell Lung Cancer. Curr. Treat. Options Oncol. 2019, 20, 21. [CrossRef] [PubMed]

12. Ferrara, N.; Adams, A.P. Ten Years of Anti-Vascular Endothelial Growth Factor Therapy. Nat. Rev. Drug Discov. 2016, 15, 385–403. [CrossRef] [PubMed]

13. Jackson, A.L.; Zhou, B.; Kim, W.Y. HIF, Hypoxia and the Role of Angiogenesis in Non-Small Cell Lung Cancer. Expert Opin. Ther. Targets 2010, 14, 1047–1057. [CrossRef] [PubMed]

14. Apte, R.S.; Chen, D.S.; Ferrara, N. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell 2019, 176, 1248–1264. [CrossRef]

15. Cohen, M.H.; Gootenberg, J.; Keegan, P.; Pazdur, R. FDA Drug Approval Summary: Bevacizumab (Avastin) plus Carboplatin and Paclitaxel as First-Line Treatment of Advanced/Metastatic Recurrent Nonsquamous Non-Small Cell Lung Cancer. Oncologist 2007, 12, 713–718. [CrossRef]

16. Soria, J.-C.; Mauguen, A.; Reck, M.; Sandler, A.B.; Saijo, N.; Johnson, D.H.; Burcoveanu, D.; Fukuoka, M.; Besse, B.; Pignon, J.-P.; et al. Systematic Review and Meta-Analysis of Randomised, Phase II/III Trials Adding Bevacizumab to Platinum-Based Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer. Ann. Oncol. 2013, 24, 20–30. [CrossRef] [PubMed]

17. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer Statistics, 2020. CA Cancer J. Clin. 2020, 70, 7–30. [CrossRef]

18. Daum, S.; Hagen, H.; Naismith, E.; Wolf, D.; Pircher, A. The Role of Anti-Angiogenesis in the Treatment Landscape of Non-Small-Cell Lung Cancer—New Combinational Approaches and Strategies of Neovessel Inhibition. Front. Cell Dev. Biol. 2020, 8, 610903. [CrossRef]

19. Fujiyo, Y.; Walsh, K. Akt Mediates Cytoprotection of Endothelial Cells by Vascular Endothelial Growth Factor in an Anchorage-Dependent Manner. J. Biol. Chem. 1999, 274, 16349–16354. [CrossRef]

20. Rafii, S.; Lyden, D.; Benezra, R.; Hattori, K.; Heissig, B. Vascular and Haematopoietic Stem Cells: Novel Targets for Anti-Angiogenesis Therapy? Nat. Rev. Cancer 2002, 2, 826–835. [CrossRef] [PubMed]

21. Bertolini, F.; Shaked, Y.; Mancuso, P.; Kerbel, R.S. The Multifaceted Circulating Endothelial Cell in Cancer: Towards Marker and Target Identification. Nat. Rev. Cancer 2006, 6, 835–845. [CrossRef] [PubMed]

22. Gerber, H.P.; McMurtrey, A.; Kowalski, J.; Yan, M.; Keyt, B.A.; Dixit, V.; Ferrara, N. Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway. Requirement for Flk-1/KDR Activation. J. Biol. Chem. 1998, 273, 30336–30343. [CrossRef] [PubMed]

23. Chen, D.S.; Hurwitz, H. Combinations of Bevacizumab with Cancer Immunotherapy. Cancer J. 2018, 24, 193–204. [CrossRef] [PubMed]

24. Hegde, P.S.; Wallin, J.J.; Manco, C. Predictive Markers of Anti-VEGF and Emerging Role of Angiogenesis Inhibitors as Immunotherapeutics. Semin. Cancer Biol. 2018, 52, 117–124. [CrossRef] [PubMed]
25. Goveia, J.; Rohlenova, K.; Taverna, F.; Treps, L.; Conradi, L.-C.; Pircher, A.; Geldhof, V.; de Rooij, L.P.M.H.; Kalуча, J.; Sokol, L.; et al. An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates. *Cancer Cell* 2020, 37, 21–36.e13. [CrossRef]

26. Allen, E.; Jabouille, A.; Rivera, L.B.; Lodewijckx, I.; Missiaen, R.; Steri, V.; Feyen, K.; Tawney, J.; Hanahan, D.; Michael, I.P.; et al. Combined Antiangiogenic and Anti-PD-L1 Therapy Stimulates Tumor Immunity through HEV Formation. *Sci. Transl. Med.* 2017, 9, eaak6979. [CrossRef]

27. Schmittnaegel, M.; Rigamonti, N.; Kadioglu, E.; Cassar, A.; Wyser Rmili, C.; Kialalainen, A.; Kienast, Y.; Mueller, H.-J.; Ooi, C.-H.; Laoui, D.; et al. Dual Angiopoietin-2 and VEGFA Inhibition Elicits Antitumor Immunity That Is Enhanced by PD-1 Checkpoint Blockade. *Sci. Transl. Med.* 2017, 9, eaak6979. [CrossRef]

28. Watanabe, H.; Ichihara, E.; Kayatani, H.; Makimoto, G.; Ninomiya, K.; Nishii, K.; Higo, H.; Ando, C.; Okawa, S.; Nakasuka, T.; et al. VEGFR2 Blockade Augments the Effects of Tyrosine Kinase Inhibitors by Inhibiting Angiogenesis and Oncogenic Signaling in Oncogene-Driven Non-Small-Cell Lung Cancers. *Cancer Sci.* 2021, 112, 1853–1864. [CrossRef]

29. Hrustanovic, G.; Olivas, V.; Pazarentzos, E.; Tulpule, A.; Asthana, S.; Blakely, C.M.; Okimoto, R.A.; Lin, L.; Neel, D.S.; Sabnis, A.; et al. RAS- MAPK Dependence Underlies a Rational Polytherapy Strategy in EML4-ALK-Positive Lung Cancer. *Nat. Med.* 2015, 21, 1038–1047. [CrossRef]

30. Abid, M.R.; Guo, S.; Minami, T.; Spokes, K.C.; Ueki, K.; Skurc, K.; Walsh, K.; Aird, W.C. Vascular Endothelial Growth Factor Activates PISK/Akt/Forkhead Signaling in Endothelial Cells. *Arterioscler. Thromb. Vasc. Biol.* 2004, 24, 294–300. [CrossRef]

31. Doanes, A.M.; Hegland, D.D.; Sethi, R.; Kovesdi, I.; Bruder, J.T.; Finkel, T. VEGF Stimulates MAPK through a Pathway That Is Unique for Receptor Tyrosine Kinases. *Biochem. Biophys. Res. Commun.* 1999, 255, 545–548. [CrossRef] [PubMed]

32. Martinengo, C.; Poggio, T.; Menotti, M.; Scalzo, M.S.; Mastini, C.; Ambrogio, C.; Pellegrino, E.; Riera, L.; Piva, R.; Ribatti, D.; et al. ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis. *Cancer Res.* 2014, 74, 6094–6106. [CrossRef] [PubMed]

33. Koh, J.; Jang, J.-Y.; Keam, B.; Kim, S.; Kim, M.-Y.; Go, H.; Kim, T.M.; Kim, D.-W.; Kim, C.-W.; Jeon, Y.K.; et al. EML4-ALK Enhances Programmed Cell Death-Ligand 1 Expression in Pulmonary Adenocarcinoma via Hypoxia-Inducible Factor (HIF)-1α and STAT3. *Oncology Reports* 2016, 5, e108514. [CrossRef] [PubMed]

34. van Hoppe, S.; Jamalpoor, A.; Rood, J.J.M.; Wagenaar, E.; Sparidans, R.W.; Beijnen, J.H.; Schinkel, A.H. Brain Accumulation of Osimertinib and Its Active Metabolite AZ5104 Is Restricted by ABCB1 (P-Glycoprotein) and ABCG2 (Breast Cancer Resistance Protein). *Pharmacol. Res.* 2019, 146, 104297. [CrossRef] [PubMed]

35. Wu, C.-P.; Hung, C.-Y.; Murakami, M.; Wu, Y.-S.; Lin, C.-L.; Huang, Y.-H.; Hung, T.-H.; Yu, J.-S.; Ambudkar, S.V. P-Glycoprotein Mediates Resistance to the Anaplastic Lymphoma Kinase Inhibitor Ensitinib in Cancer Cells. *Cancer Res.* 2012, 72, 2341. [CrossRef]

36. Kort, A.; Sparidans, R.W.; Wagenaar, E.; Beijnen, J.H.; Schinkel, A.H. Brain Accumulation of the EML4-ALK Inhibitor Ceritinib Is Restricted by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2). *Pharmacol. Res.* 2015, 102, 200–207. [CrossRef]

37. Tang, S.C.; Nguyen, L.N.; Sparidans, R.W.; Wagenaar, E.; Beijnen, J.H.; Schinkel, A.H. Increased Oral Availability and Brain Accumulation of the ALK Inhibitor Crizotinib by Coadministration of the P-Glycoprotein (ABC B1) and Breast Cancer Resistance Protein (ABCG2) Inhibitor Elacridar. *Int. J. Cancer* 2014, 134, 1484–1494. [CrossRef]

38. Fukumura, D.; Kloepper, J.; Amoozgar, Z.; Duda, D.G.; Jain, R.K. Enhancing Cancer Immunotherapy Using Antiangiogenics: Opportunities and Challenges. *Nat. Rev. Clin. Oncol.* 2018, 15, 325–340. [CrossRef]

39. Jain, R.K. Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers. *J. Clin. Oncol.* 2013, 31, 2205–2218. [CrossRef]

40. Ota, K.; Azuma, K.; Kawahara, A.; Hattori, S.; Iwama, E.; Tanizaki, J.; Harada, T.; Matsumoto, K.; Takayama, K.; Takamori, S.; et al. Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small-Cell Lung Cancer. *Cancer Cell* 2015, 21, 4014–4021. [CrossRef]

41. Nouri, K.; Azad, T.; Lighthoby, E.; Khanal, P.; Nicol, C.J.; Yang, X. A Kinome-Wide Screen Using a NanoLuc LATS Luminescent Biosensor Identifies ALK as a Novel Regulator of the Hippo Pathway in Tumorigenesis and Immune Evasion. *FASEB J.* 2019, 33, 12487–12499. [CrossRef] [PubMed]

42. Hong, S.; Chen, N.; Fang, W.; Zhan, J.; Liu, Q.; Kang, S.; He, X.; Liu, L.; Zhou, T.; Huang, J.; et al. Upregulation of PD-L1 by EML4-ALK Fusion Protein Mediates the Immune Escape in ALK Positive NSCLC: Implication for Optional Anti-PD-1/PD-L1 Immune Therapy for ALK-TKIs Sensitive and Resistant NSCLC Patients. *Oncoimmunology* 2016, 5, e1094598. [CrossRef] [PubMed]

43. Ma, L.; Lv, J.; Zhang, X.; Li, X.; Zhang, H.; Nong, J.; Zhang, Q.; Qin, N.; Yang, X.; et al. PD-L1 Expression and Its Regulation in Lung Adenocarcinoma with ALK Translocation. *Interdiscip. Sci.* 2019, 11, 266–272. [CrossRef] [PubMed]

44. Lopes-Coelho, F.; Martins, F.; Pereira, S.A.; Serpa, J. Anti-Angiogenic Therapy: Current Challenges and Future Perspectives. *Int. J. Mol. Sci.* 2021, 22, 3765. [CrossRef]

45. Cao, Y.; Cao, R.; Hedlund, E.-M. R Regulation of Tumor Angiogenesis and Metastasis by FGF and PDGF Signaling Pathways. *J. Mol. Med.* 2008, 86, 785–789. [CrossRef]

46. Allen, E.; Walters, I.B.; Hanahan, D. Brivanib, a Dual FGF/VEGFA Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition. *Clin. Cancer Res.* 2011, 17, 5299–5310. [CrossRef]
47. Turner, N.; Pearson, A.; Sharpe, R.; Lambros, M.; Geyer, F.; Lopez-Garcia, M.A.; Natrajan, R.; Marchio, C.; Iorns, E.; Mackay, A.; et al. FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer. *Cancer Res.* 2010, 70, 2085–2094. [CrossRef]

48. Cao, Y. Multifarious Functions of PDGFs and PDGFRs in Tumor Growth and Metastasis. *Trends Mol. Med.* 2013, 19, 460–473. [CrossRef]

49. Cantanhede, I.G.; de Oliveira, J.R.M. PDGF Family Expression in Glioblastoma Multiforme: Data Compilation from Ivy Glioblastoma Atlas Project Database. *Sci. Rep.* 2017, 7, 15271. [CrossRef]

50. Wilke, H.; Muro, K.; Van Cutsem, E.; Oh, S.C.; Bodoky, G.; Shimada, Y.; Hironaka, S.; Sugimoto, N.; Lipatov, O.; Kim, T.Y.; et al. Ramucirumab plus Paclitaxel versus Placebo plus Paclitaxel in Patients with Previously Treated Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma (RAINBOW): A Double-Blind, Randomised Phase 3 Trial. *Lancet Oncol.* 2014, 15, 1224–1235. [CrossRef]

51. Bagley, R.G.; Ren, Y.; Weber, W.; Yao, M.; Kurtzberg, L.; Pinckney, J.; Bangari, D.; Nguyen, C.; Brondyk, W.; Kaplan, J.; et al. Placental Growth Factor Uregulation Is a Host Response to Antiangiogenic Therapy. *Clin. Cancer Res.* 2011, 17, 976–988. [CrossRef] [PubMed]

52. Huang, H.; Bhat, A.; Woodnutt, G.; Lappe, R. Targeting the ANGPT-TIE2 Pathway in Malignancy. *Nat. Rev. Cancer* 2010, 10, 575–585. [CrossRef] [PubMed]

53. Jahangiri, A.; De Lay, M.; Miller, L.M.; Carbonell, W.S.; Hu, Y.-L.; Lu, K.; Tom, M.W.; Paquette, J.; Tokuyasu, T.A.; Tsao, S.; et al. Gene Expression Profile Identifies Tyrosine Kinase C-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance. *Clin. Cancer Res.* 2013, 19, 1773–1783. [CrossRef] [PubMed]

54. Bornstein, P. Thrombospondins Function as Regulators of Angiogenesis. *J. Cell Commun. Signal.* 2009, 3, 189–200. [CrossRef] [PubMed]

55. An, J.; Lv, W. Endostar (Rh-Endostatin) versus Placebo in Combination with Vinorelbine plus Cisplatin Chemotherapy Regimen in Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis. *Thorac. Cancer* 2018, 9, 606–612. [CrossRef]

56. Reck, M.; Kaiser, R.; Mellemgaard, A.; Douillard, J.-Y.; Orlov, S.; Krzakowski, M.; von Pawel, J.; Gottfried, M.; Bondarenko, I.; et al. Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Previously Treated Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma (RAINBOW): A Double-Blind, Randomised Phase 3 Trial. *Lancet Oncol.* 2014, 15, 143–155. [CrossRef]

57. Cui, J.; Cai, X.; Zhu, M.; Liu, T.; Zhao, N. The Efficacy of Bevacizumab Compared with Other Targeted Drugs for Patients with Metastatic Non-Small-Cell Lung Cancer: A Meta-Analysis of Phase III Randomized Trials. *PLoS ONE* 2011, 6, e22681. [CrossRef] [PubMed]

58. Botrel, T.E.A.; Clark, O.; Clark, L.; Paladini, L.; Faleiros, E.; Pegoretti, B. Efficacy of Bevacizumab (Bev) plus Chemotherapy (CT) Compared to CT Alone in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Systematic Review and Meta-Analysis. *Lung Cancer* 2011, 74, 89–97. [CrossRef] [PubMed]

59. Raphael, J.; Chan, K.; Karim, S.; Kerbel, R.; Lam, H.; Santos, K.D.; Saluja, R.; Verma, S. Antiangiogenic Therapy in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Phase III Randomized Trials. *Clin. Lung Cancer* 2017, 18, 345–355.e5. [CrossRef]

60. Liao, M.; et al. Docetaxel plus Nintedanib versus Placebo plus Docetaxel for Second-Line Treatment of Stage IV Non-Small-Cell Lung Cancer after Disease Progression on Platinum-Based Therapy (REVEL): A Multicentre, Double-Blind, Randomised Phase 3 Trial. *Lancet* 2014, 384, 665–673. [CrossRef]

61. Cui, J.; Cai, X.; Zhu, M.; Liu, T.; Zhao, N. The Efficacy of Bevacizumab Compared with Other Targeted Drugs for Patients with Advanced NSCLC: A Meta-Analysis from 30 Randomized Controlled Clinical Trials. *PLoS ONE* 2013, 8, e62038. [CrossRef]

62. Sandler, A.; Gray, R.; Perry, M.C.; Brahmer, J.; Schiller, J.H.; Dowlati, A.; Lilienbaum, R.; Johnson, D.H. Paclitaxel-Cisplatin Chemotherapy versus Cisplatin Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer. *J. Clin. Oncol.* 2012, 30, 4774–4782. [CrossRef] [PubMed]

63. Garon, E.B.; Ciuleanu, T.-E.; Arrieta, O.; Prabhash, K.; Syrigos, K.N.; Goksel, T.; Park, K.; Gorbunova, V.; Kowalszyn, R.D.; Pikiel, J.; et al. Ramucirumab plus Docetaxel versus Placebo plus Docetaxel for Second-Line Treatment of Stage IV Non-Small-Cell Lung Cancer. *Thorac. Cancer* 2017, 8, 976–988. [CrossRef] [PubMed]

64. Cao, Y. Multifarious Functions of PDGFs and PDGFRs in Tumor Growth and Metastasis. *Cancer Res.* 2011, 71, 345–353.e5. [PubMed] [CrossRef]

65. Garin-Chesa, P.; et al. Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Previously Treated Advanced Non-Small-Cell Lung Cancer (LUME-Lung 1): A Phase 3, Double-Blind, Randomised Controlled Trial. *Lancet Oncol.* 2014, 15, 143–155. [CrossRef]

66. Ramlau, R.; Gorbunova, V.; Ciuleanu, T.E.; Novello, S.; Ozguroglu, M.; Goksel, T.; Baldotto, C.; Bennouna, J.; Shepherd, F.A.; Le-Gueniec, S.; et al. Afiblercept and Docetaxel versus Docetaxel Alone after Platinum Failure in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial. *J. Clin. Oncol.* 2012, 30, 3640–3647. [CrossRef]

67. Belani, C.P.; Yamamoto, N.; Bondarenko, I.M.; Poltoratskaya, A.; Novello, S.; Tang, J.; Bycott, P.; Niethammer, A.G.; Ingrosso, A.; Kim, S.; et al. Randomized Phase II Study of Pemetrexed/Cisplatin with or without Axitinib for Non-Squamous Non-Small-Cell Lung Cancer. *BMC Cancer* 2014, 14, 290. [CrossRef]
69. Dy, G.K.; Mandrekar, S.J.; Nelson, G.D.; Meyers, J.P.; Adjei, A.A.; Ross, H.J.; Ansari, R.H.; Lyss, A.P.; Stella, P.J.; Schild, S.E.; et al. A Randomized Phase II Study of Gemcitabine and Carboplatin with or without Cediranib as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer: North Central Cancer Treatment Group Study N0528. *J. Thorac. Oncol.* **2013**, *8*, 79–88. [CrossRef]

70. Goss, G.D.; Arnold, A.; Shepherd, F.A.; Dediu, M.; Cieuleanu, T.-E.; Fenton, D.; Zukin, M.; Walde, D.; Laberge, F.; Vincent, M.D.; et al. Randomized, Double-Blind Trial of Carboplatin and Paclitaxel with Either Daily Oral Cediranib or Placebo in Advanced Non-Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study. *J. Clin. Oncol.* **2010**, *28*, 49–55. [CrossRef]

71. Laurie, S.A.; Solomon, B.J.; Seymour, L.; Ellis, P.M.; Goss, G.D.; Shepherd, F.A.; Boyer, M.J.; Arnold, A.M.; Clingan, P.; Laberge, F.; et al. Randomised, Double-Blind Trial of Carboplatin and Paclitaxel with Daily Oral Cediranib or Placebo in Patients with Advanced Non-Small Cell Lung Cancer: NCIC Clinical Trials Group Study BR29. *Eur. J. Cancer* **2014**, *50*, 706–712. [CrossRef] [PubMed]

72. Ramalingam, S.S.; Shafter, A.; Lee, J.; Seruga, B.; Snuderl, M.; Merlino, G.; Kris, M.G.; Clarke, S.J.; Drilon, A.; et al. Addition of Anti-Angiogenic Tyrosine Kinase Inhibitors to Chemotherapy for Patients with Advanced Non-Small-Cell Lung Cancer: NCIC Clinical Trials Group Study BR29. *Eur. J. Cancer* **2014**, *50*, 706–712. [CrossRef] [PubMed]

73. Scagliotti, G.V.; Vynnychenko, I.; Park, K.; Ichinose, Y.; Kubota, K.; Blackhall, F.; Pirker, R.; Galiulin, R.; Ciuleanu, T.-E.; Sydorenko, V.; Socinski, M.A.; Nishio, M.; Jotte, R.M.; Cappuzzo, F.; Orlandi, F.; Stroyakovskiy, D.; Nogami, N.; Rodriguez-Abreu, D.; et al. The Current Status and Study Progress of Recombinant Human Endostatin in Cancer Treatment. *Expert Rev. Anticancer. Ther.* **2021**, *21*, 461–464. [CrossRef]
88. Saito, H.; Fukuhara, T.; Furuya, N.; Watanabe, K.; Sugawara, S.; Iwasawa, S.; Tsunezuka, Y.; Yamaguchi, O.; Okada, M.; Yoshimori, K.; et al. Erlotinib plus Bevacizumab versus Erlotinib Alone in Patients with EGFR-Positive Advanced Non-Squamous Non-Small-Cell Lung Cancer (NEJ026): Interim Analysis of an Open-Label, Randomised, Multicentre, Phase 3 Trial. *Lancet Oncol.* 2019, 20, 625–635. [CrossRef]

89. Nakagawa, K.; Garon, E.B.; Seto, T.; Nishio, M.; Ponce Aix, S.; Paz-Ares, L.; Chiu, C.-H.; Park, K.; Novello, S.; Nadal, E.; et al. Ramucirumab plus Erlotinib in Patients with Untreated, EGFR-Mutated, Advanced Non-Small-Cell Lung Cancer (RELAY): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. *Lancet Oncol.* 2019, 20, 1655–1669. [CrossRef]

90. Huang, Z.; Xiong, Q.; Cui, Z.; Tao, H.; Zhang, S.; Wang, L.; Cui, P.; Chen, S.; Huang, D.; Yang, B.; et al. Efficacy and Safety of Crizotinib plus Bevacizumab in ALK/ROS-1/c-MET Positive Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Prospective Observational Study. *Am. J. Transl. Res.* 2021, 13, 1526–1534.

91. Lin, J.J.; Muzikansky, A.; Kennedy, E.; Kuberski, H.; Stober, L.L.; Wanat, A.C.; Azzoli, C.G.; Lennes, I.; Sequist, L.V.; Dagogo-Jack, I.; et al. Safety and Activity of Alectinib plus Bevacizumab in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase I/II Study. *ESMO Open* 2021, 7, 100342. [CrossRef] [PubMed]

92. Watanabe, S.; Matsumoto, N.; Koshoi, J.; Ishida, A.; Tanaka, T.; Abe, T.; Ishikawa, D.; Shoji, S.; Nozaki, K.; Ichikawa, K.; et al. MA21.05 Phase II Trial of the Combination of Alectinib with Bevacizumab in ALK-Positive Nonsquamous Non-Small Cell Lung Cancer. *J. Thorac. Oncol.* 2019, 14, S336. [CrossRef]

93. Choudhury, N.J.; Young, R.J.; Sellitti, M.; Miller, A.; Drilon, A. Lorlatinib and Bevacizumab Activity in ALK-Rearranged Lung Cancers After Lorlatinib Progression. *JCO Precis. Oncol.* 2020, 4, PO.20.00271. [CrossRef] [PubMed]

94. Patel, M.; Jabbour, S.K.; Malhotra, J. ALK Inhibitors and Checkpoint Blockade: A Cautionary Tale of Mixing Oil with Water? *J. Thorac. Dis.* 2018, 10, S2198–S2201. [CrossRef] [PubMed]

95. Fukui, T.; Tachihara, M.; Nagano, T.; Kobayashi, K. Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer. *Cancers* 2022, 14, 1184. [CrossRef] [PubMed]

96. Spreafico, A.; Hansen, A.R.; Abdul Razak, A.R.; Bedard, P.L.; Siu, L.L. The Future of Clinical Trial Design in Oncology. *Cancer Discov.* 2021, 11, 822–837. [CrossRef]

97. Levin, V.A.; Bidaut, L.; Hou, P.; Kumar, A.J.; Wefel, J.S.; Bekele, B.N.; Grewal, J.; Prabhu, S.; Loghin, M.; Gilbert, M.R.; et al. Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System. *Int. J. Radiat. Oncol. Biol. Phys.* 2011, 79, 1487–1495. [CrossRef]

98. Tanigawa, K.; Mizuno, K.; Kamenohara, Y.; Unoki, T.; Misono, S.; Inoue, H. Effect of Bevacizumab on Brain Radiation Necrosis in Anaplastic Lymphoma Kinase-Positive Lung Cancer. *Respirol. Case Rep.* 2019, 7, e00454. [CrossRef]

99. Elsayed, M.; Christopoulos, P. Therapeutic Sequencing in ALK+ NSCLC. *Pharmaceuticals* 2021, 14, 80. [CrossRef]

100. Pan, Y.; Deng, C.; Qiu, Z.; Cao, C.; Wu, F. The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer. *Front. Oncol.* 2021, 11, 713530. [CrossRef]

101. Nakasuka, T.; Ichihara, E.; Makimoto, G.; Maeda, Y.; Kiura, K. Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma. *J. Thorac. Oncol.* 2019, 14, e168–e169. [CrossRef] [PubMed]

102. Lee, J.J.-K.; Park, S.; Park, H.; Kim, S.; Lee, J.; Lee, J.; Youk, J.; Yi, K.; An, Y.; Park, I.K.; et al. Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma. *Cell* 2019, 177, 1842–1857.e21. [CrossRef] [PubMed]